Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study
- PMID: 12843150
- DOI: 10.1210/jc.2002-021663
Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study
Abstract
Stereotactic radiosurgery by gamma-knife (GK) is an attractive therapeutic option after failure of microsurgical removal in patients with pituitary adenoma. In these tumors or remnants of them, it aims to obtain the arrest of cell proliferation and hormone hypersecretion using a single precise high dose of ionizing radiation, sparing surrounding structures. The long-term efficacy and toxicity of GK in acromegaly are only partially known. Thirty acromegalic patients (14 women and 16 men) entered a prospective study of GK treatment. Most were surgical failures, whereas in 3 GK was the primary treatment. Imaging of the adenoma and target coordinates identification were obtained by high resolution magnetic resonance imaging. All patients were treated with multiple isocenters (mean, 8; range, 3-11). The 50% isodose was used in 27 patients (90%). The mean margin dose was 20 Gy (range, 15-35), and the dose to the visual pathways was always less than 8 Gy. After a median follow-up of 46 months (range, 9-96), IGF-I fell from 805 micro g/liter (median; interquartile range, 640-994) to 460 micro g/liter (interquartile range, 217-654; P = 0.0002), and normal age-matched IGF-I levels were reached in 7 patients (23%). Mean GH levels decreased from 10 micro g/liter (interquartile range, 6.4-15) to 2.9 micro g/liter (interquartile range, 2-5.3; P < 0.0001), reaching levels below 2.5 micro g/liter in 11 (37%). The rate of persistently pathological hormonal levels was still 70% at 5 yr by Kaplan-Meier analysis. The median volume was 1.43 ml (range, 0.20-3.7). Tumor shrinkage (at least 25% of basal volume) occurred after 24 months (range, 12-36) in 11 of 19 patients (58% of assessable patients). The rate of shrinkage was 79% at 4 yr. In no case was further growth observed. Only 1 patient complained of side-effects (severe headache and nausea immediately after the procedure, with full recovery in a few days with steroid therapy). Anterior pituitary failures were observed in 2 patients, who already had partial hypopituitarism, after 2 and 6 yr, respectively. No patient developed visual deficits. GK is a valid adjunctive tool in the management of acromegaly that controls GH/IGF-I hypersecretion and tumor growth, with shrinkage of adenoma and no recurrence of the disease in the considered observation period and with low acute and chronic toxicity.
Similar articles
-
Octreotide as primary therapy for acromegaly.J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40. doi: 10.1210/jcem.83.9.5109. J Clin Endocrinol Metab. 1998. PMID: 9745397 Clinical Trial.
-
Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion.J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8. doi: 10.1210/jc.2005-0311. Epub 2005 May 17. J Clin Endocrinol Metab. 2005. PMID: 15899958 Clinical Trial.
-
Long-term results of stereotactic radiosurgery in secretory pituitary adenomas.J Clin Endocrinol Metab. 2009 Sep;94(9):3400-7. doi: 10.1210/jc.2008-2772. Epub 2009 Jun 9. J Clin Endocrinol Metab. 2009. PMID: 19509108
-
[Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry].Ann Endocrinol (Paris). 2003 Dec;64(6):434-41. Ann Endocrinol (Paris). 2003. PMID: 15067248 Review. French.
-
Radiation treatment strategies for acromegaly.Neurosurg Focus. 2010 Oct;29(4):E12. doi: 10.3171/2010.7.FOCUS10124. Neurosurg Focus. 2010. PMID: 20887122 Review.
Cited by
-
An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy.Pituitary. 2008;11(1):1-11. doi: 10.1007/s11102-007-0059-1. Pituitary. 2008. PMID: 17690987
-
GH receptor antagonist: mechanism of action and clinical utility.Rev Endocr Metab Disord. 2005 Jan;6(1):5-13. doi: 10.1007/s11154-005-5219-x. Rev Endocr Metab Disord. 2005. PMID: 15711909 Review.
-
Modern techniques for pituitary radiotherapy.Rev Endocr Metab Disord. 2009 Jun;10(2):135-44. doi: 10.1007/s11154-008-9106-0. Rev Endocr Metab Disord. 2009. PMID: 18787957 Review.
-
Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.Pituitary. 2015 Jun;18(3):326-34. doi: 10.1007/s11102-014-0578-5. Pituitary. 2015. PMID: 24925503
-
Resistance to somatostatin analogs in acromegaly: an evolving concept?J Endocrinol Invest. 2006 Jan;29(1):86-93. doi: 10.1007/BF03349183. J Endocrinol Invest. 2006. PMID: 16553040 Review.